Investment Thesis
ZyVersa is in acute financial distress with negative stockholders equity of -$12.4M, a critically low current ratio of 0.03x, and only $101.8K in cash against $12.7M in liabilities. With $5.1M quarterly cash burn and near-total revenue collapse (-90% YoY), the company faces imminent solvency crisis and likely bankruptcy or catastrophic equity dilution within months.
Strengths
- Pharmaceutical sector with potential patent/pipeline assets
- Recent financial reporting (data as of 2025-12-31) provides visibility
- Company remains operational despite distress
Risks
- Negative stockholders equity indicates technical insolvency
- Critical liquidity crisis: 0.03x current ratio with inadequate cash for obligations
- Quarterly cash burn of $5.1M far exceeds remaining $101.8K cash reserves
- Revenue collapsed 90% YoY with no viable path to profitability
- High bankruptcy risk; dilutive financing or restructuring likely imminent
- Biotech development execution risk with no visible clinical progress
Key Metrics to Watch
- Cash balance and runway (critical survival metric)
- Any financing announcements or capital raises
- Quarterly cash burn rate and operating expenses
- Revenue stabilization or return to growth
- Clinical trial results and pipeline advancement
Financial Metrics
Revenue
-513.2K
Net Income
-25.0M
EPS (Diluted)
$-4.18
Free Cash Flow
-5.1M
Total Assets
347.9K
Cash
101.8K
Profitability Ratios
Gross Margin
N/A
Operating Margin
4,967.3%
Net Margin
4,862.0%
ROE
N/A
ROA
-7,172.3%
FCF Margin
996.5%
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
3,660.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-20T00:51:21.415096 |
Data as of: 2025-12-31 |
Powered by Claude AI